Degner D, Grohmann R, Bleich S, Rüther E
Psychiatrischen Klinik der Georg-August-Universität Göttingen.
MMW Fortschr Med. 2000 Dec 7;142(49-50):35-8, 40.
The new antidepressants, selective serotonin reuptake inhibitors (SSRI), selective serotonin noradrenalin reuptake inhibitors (SSNRI) and selective noradrenalin reuptake inhibitors (SNRI) have few clinically relevant side effects. Overall, the new antidepressants are better tolerated and cause fewer side effects than the classical tricyclic antidepressants (TCA). They have virtually no anticholinergic effects, a low level of toxicity, and produce no psychomotoric or cognitive impairment. Both the frequency and severity of gastrointestinal and CNS side effects, as well as tremor, are low. The results of the drug safety program (AMSP) confirm the good tolerability and low clinical side effects of these new substances.
新型抗抑郁药,即选择性5-羟色胺再摄取抑制剂(SSRI)、选择性5-羟色胺去甲肾上腺素再摄取抑制剂(SSNRI)和选择性去甲肾上腺素再摄取抑制剂(SNRI),几乎没有临床相关副作用。总体而言,新型抗抑郁药比传统三环类抗抑郁药(TCA)耐受性更好,副作用更少。它们几乎没有抗胆碱能作用,毒性较低,不会导致精神运动或认知障碍。胃肠道和中枢神经系统副作用以及震颤的发生率和严重程度都很低。药物安全项目(AMSP)的结果证实了这些新物质具有良好的耐受性和较低的临床副作用。